Gurpreet Brar C.V.

CURRICULUM VITAE

_________________________________________________

Gurpreet Brar, M.D.

**** *. ******* ****, ********, AZ. 85308

602-***-**** | *******@*****.***

EDUCATION

Masters in Business Administration/ Health Care Management 2007 – present

University of Phoenix Online, Phoenix. U.S.A.

Doctor of Medicine 1996 – 2002

Rostov State Medical University, Rostov on Don, Russia.

THERAPEUTIC EXPERIENCE

Endocrine/Metabolic: Carcinoid Syndrome and therapeutic & prescription practices.

Oncology: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Renal Cell Cancer.

Hematology: NHL, B-Cell Lymphomas, Plasma Cell Disorders, chemo induced Anemia, chemo induced Neutropenia and chemo induced Thrombocytopenia.

Pain management

Urology: Over Active Bladder

PROFESSIONAL EXPERIENCE

PPD, Glendale, AZ Clinical Research Associate (Regional) May 2008 - present

Perform and coordinate assigned aspects of the clinical monitoring process in accordance with GCPs and global SOPs to assess the safety and efficacy of investigational products and/or medical devices. Conduct site visits to determine protocol and regulatory compliance, and prepare required documentation. Develop collaborative relationships with investigative sites and client company personnel.

PPD, Morrisville, NC Clinical Research Associate (Office based) Dec 2007-May 2008

Perform and coordinate assigned aspects of the clinical monitoring process in accordance with GCPs and global SOPs to assess the safety and efficacy of investigational products and/or medical devices. Conduct site visits to determine protocol and regulatory compliance, and prepare required documentation. Develop collaborative relationships with investigative sites and client company personnel.

Palo Verde Hematology Oncology, Ltd. Glendale, AZ

Study Coordinator Jan 2006-Dec 2007

• Regulatory, Contract and Budget contact for the site.

• Screened the patients for different protocols.

• Patient education: explained the patient’s rights to them including benefits and risks of participation in the trial.

• Consented the patients, maintained the quality and the compliance of the research data according to FDA guidelines and communicated with the sponsor’s representatives.

• Received, dispensed and maintained the log of the study medication.

Healthy Teeth Family Dentistry, Glendale, AZ.

Consultant and Partner (Non-active) Jul 2006-present

• Planned and managed the budget, lease negotiation, licensing process and approvals for a new dental setup.

• Dealt with the routine inspections, insurance formalities and hired new staff.

• Set up of computer network for a paperless dental office.

• Oversaw advertising and marketing including public outreach in area neighborhoods.

PROFESSIONAL DEVELOPMENT

Training while employed at PPD is available upon request.

Prior to PPD:

• Trained in Medical Sciences to perform Physical Exams, Medical history taking and decision making.

• Trained in diagnostic radiological assessment of disease conditions.

• Trained to perform clinical ECG and EEG recordings.

COMPUTER EXPERIENCE

Siebel CTMS, MediData EDC, Inform EDC, PHT EDC, OncoEMR, Windows 95 – Vista, MS Word, Word Perfect, Power point, Excel, Access.

LANGUAGES

Proficient in English, Russian, Punjabi and Hindi.

CERTIFICATIONS

• Certified teacher of Russian Language. (2002)

MEMBERSHIPS

• American College of Healthcare Executives.

CLINICAL TRIAL EXPERIENCE

Urology: A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Short-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist XXXXX (XX mg qd and XXX mg qd) in Subjects with Symptoms of Overactive Bladder

Urology: A Phase III Randomized, Double-Blind, Parallel Group, Active Controlled, Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist XXXXX (XX mg qd and XXX mg qd) in Subjects with Symptoms of Overactive Bladder

Oncology: A twelve-week, double-blind, randomized, placebo-controlled, parallel group Phase II study comparing the safety, tolerability and beneficial effects of daily doses of Xmg and Xmg of XXX and placebo in patients with cancer Anorexia/Cachexia.

Oncology: A randomized, multicenter, Phase III study to compare the efficacy of monoclonal antibody in combination with chemotherapy to the efficacy of chemotherapy alone in patients with previously treated metastatic colorectal cancer.

Oncology: A Phase III, placebo-controlled, double blind, randomized clinical trial to evaluate the efficacy of monoclonal antibody in combination with FDA approved chemotherapeutic agent compared with same FDA approved chemotherapeutic alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy.

Oncology: A Phase III, Multicenter, Randomized, Double-blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the new Neurokinin-1Receptor antagonist in Combination with FDA approved antiemetics for the Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy.

Oncology: A prospective, randomized, double-blind stratified, placebo-controlled, multi-center, 3-arm trial of the continued efficacy and safety of bisphosphonates (every 4 weeks vs. every 12 weeks vs. placebo) in patients with documented bone metastases from breast cancer.

Oncology: A randomized discontinuation trial to determine the clinical benefit of continuation of multikinase inhibitor targeting several serine/threonine and receptor tyrosine kinase following disease progression in patients with advanced renal cell carcinoma.

Oncology: A randomized, Phase III, open label study of oral formulation of topoisomerase – I inhibitor plus whole-brain radiation therapy (WBRT) compared with WBRT alone in patients with brain metastases from non-small cell lung cancer.

Oncology: An expanded access open-label study of oral formulation of 4-anilinoquinazoline class of kinase inhibitor therapy in subjects with XXX over-expressing locally advanced or metastatic breast cancer.

Oncology: A multi-center phase III randomized, double-blind placebo-controlled study of the cancer liposome vaccine in non small cell lung cancer (NSCLC) subjects with unresectable stage III disease.

Oncology: A pivotal phase 3 observer-blind, randomized clinical trial of the efficacy and safety of viscous formulation of antiemetic (subcutaneous injection) compared to serotonin receptor antagonist for the prevention of acute-onset and delayed-onset chemotherapy-induced nausea and vomiting following the administration of either moderately or highly emetogenic chemotherapy regimens.

Oncology: Observational Study: Non-Small Cell Lung Cancer: The Impact of Ethnic Origin on Patients Being Treated Second Line with antifolate antineoplastic agent.

Oncology: A randomized, double blind, placebo controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum who are receiving first line chemo with FDA approved platinum based chemotherapy and IND or placebo.

Oncology: A Phase II trial of modified FDA approved platinum based chemotherapy regimen and monoclonal antibody IND in first line treatment of metastatic colorectal cancer.

Oncology: A Phase II, Multicenter, Randomized Clinical trial to Evaluate The Efficacy and Safety of monoclonal antibody IND in Combination with FDA approved chemotherapy regimen compared with taxoid family antineoplastic agent alone for Treatment of Recurrent or Refractory Non-small Cell Lung Cancer.

Oncology: An observational study of monoclonal antibody IND in combination with Chemotherapy for treatment of metastatic or locally advanced and unresectable colorectal adenocarcinoma.

Oncology: A study of Longitudinal Enumeration of Circulating Tumor Cells in Patients with Metastatic Colorectal Carcinomas.

Oncology: An open-label, non-comparative treatment protocol for the use of an oral formulation of multikinase inhibitor targeting several serine/threonine and tyrosine kinase receptors in patients with advanced renal cell carcinoma.

Oncology: Practice Patterns and medical management of carcinoid tumor with or without Carcinoid Syndrome: A chart review of 500 patients.

Oncology: An Observational Cohort Study of Patients with HER2-Positive Metastatic Breast Cancer.

Oncology: A randomized, open-label, controlled clinical trial of FDA approved platinum based chemotherapy regimen and monoclonal antibody with and without monoclonal antibody IND in first-line metastatic colorectal cancer.

Oncology: An observational Study of treatment, outcomes, and prognosis in Non Hodgkin’s Lymphoma patients.

Oncology: A Phase III randomized, open-label study of prostate cancer vaccine versus FDA approved chemotherapy regimen in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naïve.

Hematology/Oncology: A Phase 2 randomized, double blind, placebo controlled dose and schedule finding trial to evaluate the safety and efficacy of thrombopoietic agent treatment of chemotherapy- induced thrombocytopenia in subjects with non-small cell lung cancer already receiving FDA approved chemotherapeutic regimens.

Hematology: A phase II trial of Bisphosphonates in monoclonal gammopathy of undetermined significance.

Hematology: A Phase IV, open label, trial using FDA approved antineoplastic agent for re-treatment of multiple myeloma patients following an initial response to same antineoplastic agent.

Hematology: Randomized, open label, Phase II trial comparing monoclonal antibody plus recombinant human granulocyte-macrophage colony stimulating factor to monoclonal antibody monotherapy for the treatment of relapsed follicular B-cell lymphoma.

Hematology: Effectiveness of a comprehensive educational intervention program (EIP) to align quality standards (AQS) for the prevention of clinically significant chemotherapy induced neutropenia (CSCIN) in the community oncology practice setting.

Hematology: A randomized, open label, comparative study of FDA approved Erythropoietic agents in anemic subjects receiving chemotherapy.

Hematology: A Front-line treatment of newly-diagnosed chemotherapy-naïve non-Hodgkin's Lymphoma patients.

Hematology: A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and efficacy of thalidomide analogue in Combination with steroids in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Hematology: A prospective, open label, safety and efficacy study of combination treatment with XXX, and XXX in patients with relapsed or refractory multiple myeloma.

Hematology: A phase II, randomized, controlled, open label, once per cycle correction and maintenance dosing of erythropoietic agent in subjects with non-myeloid malignancies with anemia due to chemotherapy.

Hematology: A phase IV A multicenter, open-label, randomized trial evaluating the duration of infusion of bisphosphonate 4mg IV formulation in Multiple Myeloma patients with bone metastases.

Hematology: Phase II study of an XXX a topoisomerase I and II inhibitor that induces single strand DNA breaks for refractory and relapsed NHL.

Hematology: A retrospective chart review - Practice patterns and medical management of anemia with EPO.

Endocrine/Metabolic: Assessing the association between self-reported intention to adhere to endocrine therapy and patient prescription activity: An observational study survey.

Pain management: A Double-Blind, Placebo controlled evaluation of the efficacy, safety and tolerability of bio-erodable buccal patch of opioid formulation in the treatment of breakthrough pain in cancer subjects.

Pain management: An open label, long term evaluation of the efficacy, safety and tolerability of of bio-erodable buccal patch of opioid formulations in the treatment of breakthrough pain in cancer subjects.

Contact this candidate